亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Efficacy of everolimus-containing chemotherapy in HER2 negative metastatic breast cancer patients with PI3K/AKT/mTOR mutations: A retrospective study.

依维莫司 PI3K/AKT/mTOR通路 医学 乳腺癌 PTEN公司 肿瘤科 内科学 化疗 蛋白激酶B 转移性乳腺癌 癌症 癌症研究 生物 细胞凋亡 生物化学
作者
Rong Wang,Xiaojia Wang,Zhanhong Chen,Jin Niu,Yu‐An Huang,Jiani Pan,Wei-Wu Ye,Wen‐Ming Cao
出处
期刊:Journal of Clinical Oncology [American Society of Clinical Oncology]
卷期号:39 (15_suppl): e13069-e13069
标识
DOI:10.1200/jco.2021.39.15_suppl.e13069
摘要

e13069 Background: The PI3K/AKT/mTOR pathway is frequently altered in breast cancer. Everolimus is a selective inhibitor of mammalian target of Rapamycin (mTOR).The benefit of everolimus in metastatic breast cancer patients with PI3K/AKT/mTOR mutations remains unclear, especially in TNBC patients. Our study aimed to investigate the efficacy of the everolimus-containing chemotherapy in metastatic breast cancer patients with PI3K/AKT/mTOR mutations. Methods: 13 cases of HER2- metastatic breast cancer with PI3K/AKT/mTOR mutations treated with everolimus-containing chemotherapy were analyzed. The genetic profile in PI3K/AKT/mTOR pathway was studied. Results: Overall, 4 cases were hormone receptor (HR) positive and 9 were TNBC. 7 patients only had PIK3CA mutations, 1 patient had only PIK3R1 mutations, and 5 patients had other mutations in the pathway in addition to PIK3CA, including PTEN, PIK3CB, CTNNB1, FGFR1 and TSC2. 5 cases were treated as first or second line chemotherapy, and 8 were as third line or above. The ORR (CR+PR) was 38.5% (5/13), and DCR (CR+PR+SD) was 84.6% (11/13), including 5 cases of PR, 6 cases of SD, and 2 cases of PD. The median PFS was 5.8 months (95% CI 3.7-9.7), and the median OS was 14.3 months (95% CI 6.47-null). However, the ORR of TNBC patients was higher than that of HR-positive, which were 44.4% (4/9) and 25% (1/4), respectively ( p = 0.070). The mPFS was also longer than that of HR-positive with 5.8 months versus 1.7 months, as well as the mOS with 14.3 versus 3.8 months. We also found that the patients carrying other mutations besides PIK3CA in the PI3K/AKT/mTOR pathway had a longer PFS compared to the patients without other mutations, which was 9.7 months and 4.3 months respectively ( p = 0.272). And the DCR of the two groups were 100% and 75% respectively ( p = 0.451). Conclusions: We found that everolimus-containing chemotherapy was effective in the treatment of HER2- metastatic breast cancer with PI3K/AKT/mTOR pathway activation. TNBC patients had a trend of longer mPFS than HR+ patients. And the patients carrying other mutations besides PIK3CA in the PI3K/AKT/mTOR pathway have a trend of longer PFS and higher DCR compared to the patients without other mutations. However, trails with larger samples are needed for further verification.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
慕青应助科研通管家采纳,获得10
58秒前
1分钟前
1分钟前
1分钟前
lourahan发布了新的文献求助10
3分钟前
3分钟前
酷波er应助bukeshuo采纳,获得10
4分钟前
lourahan发布了新的文献求助10
4分钟前
NexusExplorer应助科研通管家采纳,获得10
4分钟前
方琼燕完成签到 ,获得积分10
5分钟前
5分钟前
WWXWWX发布了新的文献求助10
6分钟前
6分钟前
moufei完成签到,获得积分10
7分钟前
L_x完成签到 ,获得积分10
7分钟前
悦耳十三发布了新的文献求助10
8分钟前
悦耳十三完成签到,获得积分10
8分钟前
8分钟前
8分钟前
JamesPei应助科研通管家采纳,获得10
8分钟前
ding应助糊涂的清醒者采纳,获得10
9分钟前
WWXWWX发布了新的文献求助10
9分钟前
9分钟前
9分钟前
哈哈发布了新的文献求助20
10分钟前
Lxy发布了新的文献求助50
11分钟前
哈哈完成签到,获得积分10
11分钟前
君寻完成签到 ,获得积分10
11分钟前
研友_8y2G0L完成签到,获得积分20
11分钟前
Diligency完成签到 ,获得积分10
11分钟前
11分钟前
情怀应助糊涂的清醒者采纳,获得10
12分钟前
poki完成签到 ,获得积分10
12分钟前
12分钟前
12分钟前
12分钟前
SciGPT应助清雨采纳,获得10
12分钟前
12分钟前
清雨发布了新的文献求助10
12分钟前
12分钟前
高分求助中
Lire en communiste 1000
Ore genesis in the Zambian Copperbelt with particular reference to the northern sector of the Chambishi basin 800
Becoming: An Introduction to Jung's Concept of Individuation 600
Briefe aus Shanghai 1946‒1952 (Dokumente eines Kulturschocks) 500
A new species of Coccus (Homoptera: Coccoidea) from Malawi 500
A new species of Velataspis (Hemiptera Coccoidea Diaspididae) from tea in Assam 500
Актуализированная стратиграфическая схема триасовых отложений Прикаспийского региона. Объяснительная записка 360
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3167188
求助须知:如何正确求助?哪些是违规求助? 2818687
关于积分的说明 7921864
捐赠科研通 2478444
什么是DOI,文献DOI怎么找? 1320323
科研通“疑难数据库(出版商)”最低求助积分说明 632748
版权声明 602438